The GI side effects that occur at higher doses without titration are significant enough to derail adherence completely
Both use the same once-weekly injection schedule
Keywords such as "Tirzepatide," "GIP/GLP-1 receptor agonist," "Type 2 diabetes mellitus," "glycemic control," "weight loss," and "cardiovascular outcomes" were used
Research in cell and tissue models has characterized effects on hepatic lipid-metabolism signaling, lipolysis pathways in adipose-tissue research, and the glucose-insulin signaling axis at the cellular level
A New Metabolic Paradigm Retatrutide represents a new metabolic paradigm
Once released, GLP-1 performs several important metabolic functions